Medical Devices industry M&A deals total $3.86bn globally in March 2021

Total medical devices industry M&A deals worth $3.86bn were announced globally in March 2021, led by Boston Scientific’s $1.07bn asset transaction with Lumenis, according to GlobalData’s deals database.

The value marked an increase of 39.4% over the previous month of $2.77bn and a drop of 49.3% when compared with the last 12-month average, which stood at $7.61bn.

Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.41bn. At the country level, the US topped the list in terms of deal value at $2.23bn.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in March 2021 was the US with 23 deals, followed by the Germany with four and Canada with three.

In 2021, as of March, medical devices M&A deals worth $30.7bn were announced globally, marking an increase of 1029.1% year on year.

medical devices industry M&A deals in March 2021: Top deals

The top five M&A deals accounted for 72.5% of the overall value during March 2021.

The combined value of the top five medical devices M&A deals stood at $2.8bn, against the overall value of $3.86bn recorded for the month.

The top five medical devices industry M&A deals of March 2021 tracked by GlobalData were:

1) Boston Scientific’s $1.07bn asset transaction with Lumenis

2) The $695m acquisition of Resolution Bioscience by Agilent Technologies

3) Agiliti’s $475m acquisition of Northfield Medical

4) The $320m acquisition of Asuragen by Bio Techne

5) Organon &’s acquisition of Alydia Health for $240m.